|
Real-time Estimate
Cboe BZX
10:52:48 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 70.08 USD | -1.29% |
|
-4.59% | -14.75% |
Company Valuation: Tarsus Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 465.2 | 391 | 670.4 | 2,117 | 3,476 | 3,115 | - | - |
| Change | - | -15.95% | 71.44% | 215.74% | 64.21% | -10.37% | - | - |
| Enterprise Value (EV) 1 | 465.2 | 391 | 472.1 | 1,894 | 3,476 | 2,779 | 2,640 | 2,422 |
| Change | - | -15.95% | 20.74% | 301.19% | 83.5% | -20.05% | -5.02% | -8.25% |
| P/E | -33.6x | -5.82x | -4.38x | -18x | -51.5x | -14.8x | 532x | 19.7x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | -0.1x | 0.5x | 1.1x | -0x | -5x | 0x |
| Capitalization / Revenue | 8.16x | 15.1x | 38.4x | 11.6x | 7.7x | 4.28x | 3.39x | 2.73x |
| EV / Revenue | 8.16x | 15.1x | 27.1x | 10.4x | 7.7x | 3.82x | 2.87x | 2.12x |
| EV / EBITDA | -39.3x | -6.27x | -3.32x | -15.8x | -50.3x | -29.5x | 58.1x | 19.6x |
| EV / EBIT | -38.3x | -6.24x | -3.3x | -15.7x | -49x | -11.2x | 67x | 12.9x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.67 | -2.52 | -4.62 | -3.07 | -1.59 | -4.788 | 0.1333 | 3.6 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 57.03 | 25.82 | 17.45 | 183 | 451.4 | 727.5 | 920 | 1,141 |
| EBITDA 1 | -11.84 | -62.39 | -142.3 | -119.8 | -69.15 | -94.3 | 45.39 | 123.6 |
| EBIT 1 | -12.16 | -62.71 | -143.2 | -120.6 | -70.97 | -247.4 | 39.43 | 187.7 |
| Net income 1 | -13.83 | -62.09 | -135.9 | -115.6 | -66.42 | -215 | 9.619 | 203 |
| Net Debt 1 | - | - | -198.3 | -222.5 | - | -336.3 | -475.6 | -693.3 |
| Reference price 2 | 22.50 | 14.66 | 20.25 | 55.37 | 81.88 | 70.99 | 70.99 | 70.99 |
| Nbr of stocks (in thousands) | 20,677 | 26,672 | 33,105 | 38,227 | 42,449 | 43,883 | - | - |
| Announcement Date | 3/14/22 | 3/13/23 | 2/27/24 | 2/25/25 | 2/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -14.83x | 3.82x | -29.47x | -.--% | 3.12B | |
| 35.8x | 12.9x | 27.02x | 0.55% | 1,116B | |
| 37.07x | 6.25x | 17.38x | 2.11% | 610B | |
| 36.17x | 8.31x | 17.13x | 2.45% | 501B | |
| 112.15x | 5.92x | 25.35x | 2.35% | 358B | |
| 20.49x | 5x | 12.4x | 2.64% | 366B | |
| 21.24x | 5.55x | 13.66x | 2.88% | 288B | |
| 22x | 4.43x | 12.71x | 1.99% | 261B | |
| 27.56x | 7.08x | 12.68x | 2.32% | 235B | |
| -45.98x | 7.04x | 27.26x | 2.1% | 195B | |
| Average | 25.17x | 6.63x | 13.61x | 1.94% | 393.29B | |
| Weighted average by Cap. | 35.00x | 8.17x | 19.94x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- TARS Stock
- Valuation Tarsus Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
